Knott David M Jr Purchases 90,000 Shares of Xeris Biopharma Holdings, Inc. $XERS

Posted by Brenda Bartman on Jul 24th, 2026

Knott David M Jr lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 9.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,060,000 shares of the company’s stock after buying an additional 90,000 shares during the period. Xeris Biopharma makes up approximately 3.6% of Knott David M Jr’s portfolio, making the stock its 6th largest position. Knott David M Jr owned about 0.61% of Xeris Biopharma worth $6,148,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC increased its stake in Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp raised its position in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after purchasing an additional 378,595 shares during the period. Qube Research & Technologies Ltd raised its position in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after purchasing an additional 185,063 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $8.41 on Friday. The firm’s 50 day moving average price is $7.25 and its 200-day moving average price is $6.75. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. Xeris Biopharma Holdings, Inc. has a one year low of $4.87 and a one year high of $10.08. The firm has a market cap of $1.45 billion, a P/E ratio of 140.17 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.80.

Check Out Our Latest Analysis on XERS

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Monday, June 1st. The stock was sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the sale, the insider directly owned 1,176,506 shares of the company’s stock, valued at approximately $7,129,626.36. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider owned 1,691,126 shares in the company, valued at $13,579,741.78. This represents a 5.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 251,500 shares of company stock valued at $1,846,457. Corporate insiders own 4.35% of the company’s stock.

About Xeris Biopharma

(Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.